CN1857274A - Medicine composition for treating valval and/or vaginal infection - Google Patents
Medicine composition for treating valval and/or vaginal infection Download PDFInfo
- Publication number
- CN1857274A CN1857274A CN 200610072089 CN200610072089A CN1857274A CN 1857274 A CN1857274 A CN 1857274A CN 200610072089 CN200610072089 CN 200610072089 CN 200610072089 A CN200610072089 A CN 200610072089A CN 1857274 A CN1857274 A CN 1857274A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- promestriene
- pharmaceutical composition
- daily dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010046914 Vaginal infection Diseases 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title abstract description 20
- 239000000203 mixture Substances 0.000 title abstract description 13
- 229940079593 drug Drugs 0.000 title description 9
- KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 title 1
- 108010021889 valylvaline Proteins 0.000 title 1
- 229960000282 metronidazole Drugs 0.000 claims abstract description 31
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 29
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 29
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960004765 promestriene Drugs 0.000 claims abstract description 25
- IUWKNLFTJBHTSD-AANPDWTMSA-N promestriene Chemical compound C1C[C@]2(C)[C@@H](OC)CC[C@H]2[C@@H]2CCC3=CC(OCCC)=CC=C3[C@H]21 IUWKNLFTJBHTSD-AANPDWTMSA-N 0.000 claims abstract description 25
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000000829 suppository Substances 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 15
- 210000001215 vagina Anatomy 0.000 abstract description 13
- 208000002003 vulvitis Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- -1 metronidazole compound Chemical class 0.000 description 15
- 229960003260 chlorhexidine Drugs 0.000 description 14
- 241000700159 Rattus Species 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000007901 soft capsule Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000003871 white petrolatum Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 4
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to medicine composition, and especially a kind of medicine composition for treating vulval and/or vaginal infection. The daily dose of the medicine composition includes promestriene 5-10 mg, preferably 8 mg; chlorhexidine acetate 3-8 mg, preferably 6 mg; and metronidazole 100-200 mg, preferably 160 mg. The medicine composition is prepared preferably into vagina administrating preparation forms, such as suppository, capsule, tablet, etc.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, be specifically related to a kind of externally-applied medicinal composition for the treatment of pudendum and/or vaginal infection, it is an active component with promestriene, chlorhexidine acetate and metronidazole.
Background technology
It is women's commonly encountered diseases and frequently-occurring disease that gynecological's V﹠V catches, and its sickness rate rises year by year.Chlorhexidine acetate/metronidazole compound preparation is the common drug of this class disease of treatment.These formulation example are if any Chlorhexidine Compound, metronidazole,clotrimazole and chlorhexidine acetate suppositories agent etc., and wherein chlorhexidine acetate is that the content of 8mg/ grain, metronidazole is the 200mg/ grain, is used for the treatment of the various vaginitiss that pathogen such as various antibacterials, anaerobe, mycete, infusorian cause.But chlorhexidine acetate/metronidazole compound preparation just treatment early stage catch the time, effect is apparent in view, and treatment is heavier catch on effect be not very desirable, and chlorhexidine acetate/metronidazole compound preparation is in the colpitic while of treatment, demonstrate bigger untoward reaction, show as the local excitation of vagina greatlyyer, produce local red and swollen phenomenon.
Summary of the invention
The inventor is in order to address the aforementioned drawbacks, on the basis of Chlorhexidine Compound system, discover with promestriene, chlorhexidine acetate, metronidazole to be that the preparation that active component is developed can solve two above-mentioned problems effectively through a large amount of sciences, not only can lower untoward reaction, and on the heavier gynecological infection of treatment, effect is remarkable, can also shorten simultaneously and treat the course of treatment, cure rate significantly improves, and has improved the effect of treatment.
Therefore, an object of the present invention is to provide a kind of pharmaceutical composition, specifically be to be the externally-applied medicinal composition of active component, be used for the treatment of pudendum and/or vaginal infection, thereby select for doctor and patient provides a kind of better medication with promestriene, chlorhexidine acetate, metronidazole.
The present invention has realized above-mentioned purpose by following a kind of pharmaceutical composition for the treatment of pudendum and/or vaginal infection is provided, and it is that 3～8mg chlorhexidine acetate and daily dose are 100～200mg metronidazole that described compositions comprises promestriene, the daily dose that daily dose is 5～10mg.
In the pharmaceutical composition of the present invention, the daily dose of promestriene is preferably 7～9mg, most preferably is 8mg; The daily dose of chlorhexidine acetate is preferably 5～7mg, most preferably is 6mg; The daily dose of metronidazole is preferably 120～180mg, most preferably is 160mg.
Pharmaceutical composition of the present invention can be prepared into the dosage form of intravaginal administration, and these dosage forms are including, but not limited to suppository, capsule, tablet, emulsifiable paste and washing liquid.
Contained chlorhexidine mainly is very strong to the aerobe inhibitory or killing effect in the compositions of the present invention, comprises dysentery bacterium, Bacillus typhi, staphylococcus aureus, gonococcus, streptococcus, bacillus pyocyaneus etc.It also has certain effect to anaerobe such as vulnerability bacillus, bacteroides thetaiotaomicron and some non-spore shape anaerobe.Many funguses have also showed certain sensitivity to it.People such as Bernstein report, the chlorhexidine of 0.12% concentration has obvious effect to herpes simplex virus, cytomegalovirus, influenza sexually transmitted disease (STD) poison, gray nucleus virus etc.Bibliographical information, chlorhexidine also has inhibitory or killing effect to infusorian.
Contained metronidazole has the obvious sterilization effect to the anaerobe that causes gynaecopathia such as Bacteroides, Peptostreptococcus genus, Clostridium etc. in the pharmaceutical composition of the present invention, is treatment is recommended by The World Health Organization (WHO) to anaerobic infection choice drug.Some aerobe such as corynebacterium vaginale, peptostreptococcus, staphylococcus aureus also there is certain inhibitory or killing effect.Metronidazole is the treatment ameba insect infection of generally acknowledging at present, the choice drug that trichomonas vaginitis infects.
When contained promestriene is used for skin and mucosa in the pharmaceutical composition of the present invention, activity with the excessive dermatitis of significant local nutrition and lipotropism, when being used for gynecological, promote the differentiation and the maturation of vagina epithelium mucomembranous cell, promoted the growth of body to recover, strengthened the immunocompetence of body, strengthen the antimicrobial ability of body itself and avoided estrogenic ill effect, promestriene also has effect synthetic and the secretion glycogen, and can promote DoderleinShi bacillus (vagina bacillus acidophilus's) regeneration, and produce lactic acid, stimulate to have changed intravaginal sour environment, destroy the anti-condition of flora, the breeding of flora is weakened with existence.
Adopt pharmaceutical composition of the present invention, can reach and enlarge antimicrobial spectrum and complementary action is arranged, strengthen the ability of killing that presses down greatly to various pathogenic bacterium, the nutritious tonifying function of promestriene makes body self produce repair function, strengthened the immunocompetence of self, improved the antibacterial ability of body self, simultaneously balance local irritant untoward reaction.
Favourable part of the present invention is that effect is remarkable aspect the treatment vaginal infection, can also shorten simultaneously and treat the course of treatment, significantly improves cure rate, and is also easy to carry and use in addition, helps strengthening the compliance of patient to therapeutic scheme.
Specific embodiments
Below specify various aspects of the present invention and feature by preferred embodiment.It should be appreciated by those skilled in the art that these embodiment just are used for illustration purpose, and do not limit the scope of the invention.Protection scope of the present invention only is subjected to the restriction of claims.Under the condition that does not deviate from claims scope.Those skilled in the art can carry out various modifications and improvement to various aspects of the present invention, and these modifications and improvement also belong to protection scope of the present invention.For instance; though in the embodiment of the invention pharmaceutical composition of the present invention is made soft capsule; but those skilled in the art is after reading present specification; to be easy to prepare other forms of pharmaceutical compositions of the present invention such as suppository, tablet, emulsifiable paste, washing liquid, so these dosage forms are positioned within protection scope of the present invention according to description of the invention.
In addition, unless it should be noted that and specialize, below among the embodiment used various materials and reagent all be material and reagent commonly used in this area, can obtain by conventional commercial sources; Method therefor is and well known to a person skilled in the art conventional method.
Embodiment 1: the preparation of promestriene/chlorhexidine acetate/metronidazole compound capsules
Take by weighing the husky alkane of white vaseline and the 80% jiao heating for dissolving of putting together respectively, be incubated about 60 ℃, standby, be 1 liquid.The husky alkane in angle that takes by weighing chlorhexidine acetate, metronidazole and surplus is in the same place, stir, chlorhexidine acetate, metronidazole are dissolved fully, add again after promestriene stirs it, add sorbitan sesquioleate, the ethyl hydroxybenzoate of having weighed then, after the stirring and dissolving, mix with 1 liquid, fully mix with the high speed dispersing emulsification machine, promptly make content.Add gelatin, glycerol, water, ethyl hydroxybenzoate according to the prescription of determining, in about 60 ℃, change glue, and the glue vacuum outgas is handled, for using on the soft gelatin capsule press machine.Medicinal liquid and glue are incorporated in the capsular machine of preparation, regulate this machine and make the medicinal liquid that injects formula ratio in each soft capsule, preparation contains the soft capsule of promestriene, chlorhexidine acetate, metronidazole in gelatin shell.Oils and fats with ethanol flush away soft gelatin capsule surface.
Prescription 1
Constituent content (g/1000 grain)
Promestriene 10
Chlorhexidine acetate 7
Metronidazole 150
Vaseline 160
Semi-synthetic fatty acid 100
Paraffin adds to 2000mg
Make 1000
Prescription 2
Constituent content (g/1000 grain)
Promestriene 8
Chlorhexidine acetate 6
Metronidazole 120
White vaseline 150
Semi-synthetic fatty acid 100
Paraffin adds to 2000mg
Make 1000
Prescription 3
Constituent content (g/100 grain)
Promestriene 10
Chlorhexidine acetate 5
Metronidazole 170
White vaseline 150
White vaseline 150
Semi-synthetic fatty acid 100
Paraffin adds to 2000mg
Make 1000
Prescription 4
Constituent content (mg/ grain)
Promestriene 5
Chlorhexidine acetate 7
Metronidazole 180
White vaseline 150
Semi-synthetic fatty acid 100
Paraffin adds to 2000mg
Make 1000
The prescription of prescription 5, clinical research:
Constituent content (mg/ grain)
Promestriene 8
Chlorhexidine acetate 6
Metronidazole 160
White vaseline 150
Semi-synthetic fatty acid 100
Paraffin adds to 2000mg
Make 1000
Embodiment 2: stability experiment
To be placed on temperature by the 3 aluminum-plastic packaged batch samples of prescription 5 preparations among the embodiment 1 is that 30 ± 2 ℃, relative humidity are 60% ± 5 ℃ of (NaNO
2Saturated solution) in the calorstat, the 1st, 2,3,6 sampling at the end of month, detects respectively by relevant study on the stability project.The results are shown in following table 1.
Table 1
| Lot number | Storage time (moon) | The investigation project | ||||||
| Outward appearance | The content character | Catabolite | The molten change time limit (branch) | Indicate content (%) | ||||
| Promestriene | Chlorhexidine acetate | Metronidazole | ||||||
| 040901 | 0 | Oval | Oily liquids | Do not have | 12 | 98.56 | 110.08 | 96.11 |
| 1 | Oval | Oily liquids | Do not have | 11 | 98.32 | 109.02 | 96.37 | |
| 2 | Oval | Oily liquids | Do not have | 13 | 97.96 | 108.33 | 96.27 | |
| 3 | Oval | Oily liquids | Do not have | 12 | 97.68 | 107.46 | 95.69 | |
| 6 | Oval | Oily liquids | Do not have | 11 | 97.46 | 107.32 | 95.68 | |
| 040902 | 0 | Oval | Oily liquids | Do not have | 13 | 98.79 | 108.29 | 96.78 |
| 1 | Oval | Oily liquids | Do not have | 11 | 98.67 | 107.96 | 96.78 | |
| 2 | Oval | Oily liquids | Do not have | 12 | 98.56 | 107.48 | 96.68 | |
| 3 | Oval | Oily liquids | Do not have | 11 | 98.46 | 107.17 | 96.47 | |
| 6 | Oval | Oily liquids | Do not have | 12 | 97.69 | 106.97 | 95.96 | |
| 040903 | 0 | Oval | Oily liquids | Do not have | 13 | 97.86 | 104.56 | 98.33 |
| 1 | Oval | Oily liquids | Do not have | 12 | 97.77 | 104.27 | 97.96 | |
| 2 | Oval | Oily liquids | Do not have | 10 | 97.65 | 103.87 | 97.83 | |
| 3 | Oval | Oily liquids | Do not have | 11 | 97.54 | 103.75 | 97.81 | |
| 6 | Oval | Oily liquids | Do not have | 13 | 97.43 | 103.6 | 96.98 |
Above stability test result shows that this compound preparation stability is better, and character is very stable under aluminum-plastic packaged, room temperature, drying condition.
Embodiment 3: local excitation and toxicity research
According to the 5 preparation experiment soft capsules of the prescription among the embodiment 1, wherein comprise promestriene 8mg, chlorhexidine acetate 6mg, metronidazole 160mg.Every preparation contains medicine composition 174mg, and every preparation is about 2.000g.((0.225～0.270kg) carries out local excitation and toxicity test for laboratory animal to compound capsules for body weight 2.20～2.60kg) and female rats to adopt the Female rabbits that Huaxi Medical Univ's animal center test chamber provides.
Use the content conduct of the compound capsules of above-mentioned preparation to be subjected to the reagent thing; Use Chlorhexidine Compound as the positive control medicine, administration and dosage are equivalent to chlorhexidine acetate 6mg, metronidazole 160mg; Use and do not contain the substrate inert matter soft capsule of medicine as negative control.
In the experiment, be subjected to the reagent thing to be divided into following high, medium and low three dosage:
High dose: every rabbit administration every day 1.0g, single administration 0.5g, every day twice, ingredient 87mg, average 36.25mg/kg is 20 times of people's consumption.Every rat single administration 0.2g, (about 0.2g) ingredient 17.4mg once a day, average 72.5mg/kg is 40 times of people's consumption.
In dosage: every rabbit administration every day 0.5g, single administration 0.25g, every day twice, ingredient 43.5mg, average 18.13mg/kg is 9.5 times of people's consumption.Every rat single administration 0.1g, (about 0.1g) ingredient 8.7mg once a day, average 36.25mg/kg is 20 times of people's consumption.
Low dosage: every rabbit administration every day 0.2g, single administration 0.1g, every day twice, ingredient 17.4mg, average 7.25mg/kg is 3.8 times of people's consumption.Every rat single administration 0.05g, (about 0.05g) ingredient 4.35mg once a day, average 18.13mg/kg is 10 times of people's consumption.
20 times of the dosage behaviour consumption of positive control drug.
20 Female rabbits and 30 female rats are divided into 5 groups at random, every group of 4 rabbit and 6 rat.Be subjected to examination group and negative control group to inject medicine with the 1ml syringe to intravaginal, rabbit is administered twice/sky, observes 7 days.Leading indicator be animal activity, feed, defecation, fur, vagina outward appearance, to have or not edema, hyperemia, ulceration and secretions to have no abnormal etc.
Sacrificed by exsanguination rabbit after the last administration, rat is put to death in the cervical vertebra dislocation.1. dissect pelvic cavity perusal reproductive system and the surrounding tissue organ has or not abnormal phenomenas such as edema, hyperemia, erosion; 2. dissect ANOMALOUS VARIATIONS such as vagina perusal vaginal walls color, edema, hyperemia, erosion, ulcer; 3. win part animal vagina and carry out pathological section, and observe, take a picture.
Found that: at administration and viewing duration, test group and control animals activity, feed, defecation, fur etc. are all no abnormal, body weight, breathing, heart rate, Non Apparent Abnormality.Vagina is dissected the perusal result and is shown that test group do not have abnormal phenomenas such as hyperemia, swelling and surrounding tissue adhesion, and matched group has slight red and swollen phenomenon.Vagina pathology structure observation shows no abnormal pathological change.
From The above results as can be seen, compound capsules of the present invention and negative control are not seen vagina local excitation symptom, do not have the toxicity phenomenon, and Chlorhexidine Compound have slight local excitation symptom yet, illustrate that compound capsules of the present invention is more safer than Chlorhexidine Compound.
Embodiment 4: the long term toxicity research of local application
Be subjected to the reagent thing: the same
High dose: every rat single administration 0.2g, (about 0.2g) ingredient 17.4mg once a day, average 72.5mg/kg is 40 of people's consumption.
In dosage: every rat single administration 0.1g, (about 0.1g) ingredient 8.7mg once a day, average 36.25mg/kg is 20 times of people's consumption.
Low dosage: every rat single administration 0.05g, (about 0.05g) ingredient 4.35mg once a day, average 18.13mg/kg is 10 times of people's consumption.
Three dosage are administered once every day, observed continuously 30 days, and repeated trials three times, its result shows that animal whole body and vagina part there is no toxic reaction and local irritation; Pathological change is not seen in section film-making and microscopic examination yet, shows that three dosage group medicines do not have pathogenic effects to each layer of vagina.
Embodiment 5: clinical research
Owing to studies show that, Chlorhexidine Compound is mainly treated trichomonal vaginitis, colpitis mycotica, nonspecific vaginitis and senile vaginitis, therefore, according to four kinds of diseases, Chlorhexidine Compound and compound capsules have been designed contrast test, one tame hospital has carried out clinical research to 160 example aspiration patients in Sichuan, wherein matched group is one group, one group of test group, every group of each 80 routine patient, every group is divided the trichomonal vaginitis group again, the colpitis mycotica group, each 20 example of nonspecific vaginitis group and the every group of senile vaginitis group, the patient satisfies the requirement of clinical research, and selected patient infection's degree is all heavier; Test group each group corresponding with matched group before treatment, the equal no difference of science of statistics of symptom, sign and lab testing, during the treatment and treatment back all is the index of judgement with symptom, sign and lab testing.
Curative effect determinate standard is as follows:
Cure: symptom complete obiteration, lab testing feminine gender.
Effectively: the symptom complete obiteration, but the lab testing positive or symptom are obviously alleviated the lab testing feminine gender.
Invalid: symptom does not have improvement, the lab testing positive.
Use is subjected to the reagent thing according to compound capsules (the containing promestriene 8mg+ chlorhexidine acetate 6mg+ metronidazole 160mg) conduct of 5 preparations of the prescription among the embodiment 1, with finger medicinal soft capsule is sent into the vagina deep by the experimenter before sleeping evening, take measures to prevent medicine liquid leakage, once a day, continuous six days is a course of treatment.
Use Chlorhexidine Compound medicine in contrast, it is suitable that each administration and trial drug feed dosage, i.e. chlorhexidine acetate 6mg and metronidazole 160mg, conduit is inserted the about 7-8cm of intravaginal gently, slowly medicinal liquid is clamp-oned intravaginal then, kept 3-5 minute, take measures to prevent medicine liquid leakage.Once a day, continuous six days is a course of treatment.
Statistical analysis: the clinical efficacy of test group and matched group, total effects are analyzed with Ridit and are compared; Add up with SAS6.12 software.
Trichomonal vaginitis research (test group 20 examples, matched group 20 examples) effect such as following table 2.
Table 2
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Trichomonal vaginitis | Test group | 20 | 17 | 85％ | 2 | 10％ | 1 | 5％ | 95％ |
| Matched group | 20 | 12 | 60％ | 4 | 20％ | 4 | 20％ | 80％ | |
Colpitis mycotica research (test group 20 examples, matched group 20 examples) effect such as following table 3.
Table 3
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Colpitis mycotica | Test group | 20 | 19 | 95％ | 1 | 5％ | 0 | 0％ | 100％ |
| Matched group | 20 | 11 | 55％ | 6 | 30％ | 3 | 15％ | 85％ | |
Nonspecific vaginitis research (test group 20 examples, matched group 20 examples) effect such as following table 4.
Table 4
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Nonspecific vaginitis | Test group | 20 | 17 | 85％ | 2 | 10 | 1 | 5％ | 95％ |
| Matched group | 20 | 13 | 65％ | 4 | 20 | 1 | 5％ | 95％ | |
Senile vaginitis research (test group 20 examples, matched group 20 examples) effect such as following table 5.
Table 5
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Senile vaginitis | Test group | 20 | 15 | 75％ | 4 | 20％ | 1 | 5％ | 95％ |
| Matched group | 20 | 14 | 70％ | 4 | 20％ | 1 | 5％ | 95％ | |
From above experimental result as can be seen, totally 37 examples of test group recovery from illness+produce effects+effectively, total effective rate is 92.5%, in the matched group, totally 31 examples of recovery from illness+produce effects+effectively, the Chlorhexidine Compound total effective rate is a significant difference significantly (p＜0.05) between 77.5%, two group.Test group is 85% on total cure rate, and matched group is 62.5%, on total cure rate significant significant difference (P＜0.05) is arranged.
In therapeutic process, test group and matched group demonstrate different total effective rates on the treatment course of treatment to the patient, see the following form 6.
Table 6
Above data show, test group on the required time, shows good advantages in the treatment curative effect; Shorten the amount and the time of medication, demonstrated cost advantage.
In the process of experiment, the Chlorhexidine Compound matched group has 7 routine patients to demonstrate slight red and swollen phenomenon, and local irritant effect is arranged, and test group does not have red and swollen stimulate phenomenon and other untoward reaction.The soft capsule that shows promestriene/miconazole has better safety.
In sum, promestriene/chlorhexidine acetate/metronidazole soft capsule and Chlorhexidine Compound relatively, on the treatment vaginal infection, more remarkable treatment effect and safety and reliability, and shortened treatment course of treatment have lowered patient's misery.
Claims (9)
1. pharmaceutical composition for the treatment of pudendum and/or vaginal infection, its promestriene, daily dose that comprises that daily dose is 5～10mg is that 3～8mg chlorhexidine acetate and daily dose are 100～200mg metronidazole.
2. the described pharmaceutical composition of claim 1, wherein the daily dose of promestriene is 7～9mg.
3. the described pharmaceutical composition of claim 2, wherein the daily dose of promestriene is 8mg.
4. the described pharmaceutical composition of claim 1, wherein the daily dose of chlorhexidine acetate is 5～7mg.
5. the described pharmaceutical composition of claim 4, wherein the daily dose of chlorhexidine acetate is 6mg.
6. the described pharmaceutical composition of claim 1, wherein the daily dose of metronidazole is 120～180mg.
7. the described pharmaceutical composition of claim 6, wherein the daily dose of metronidazole is 160mg.
8. each described pharmaceutical composition in the aforementioned claim, it is prepared into the dosage form of intravaginal administration.
9. the described pharmaceutical composition of claim 8, the dosage form of wherein said intravaginal administration is suppository, capsule, tablet, emulsifiable paste or washing liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100720898A CN100408041C (en) | 2006-04-10 | 2006-04-10 | Medicine composition for treating valval and/or vaginal infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100720898A CN100408041C (en) | 2006-04-10 | 2006-04-10 | Medicine composition for treating valval and/or vaginal infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1857274A true CN1857274A (en) | 2006-11-08 |
| CN100408041C CN100408041C (en) | 2008-08-06 |
Family
ID=37296262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100720898A Expired - Fee Related CN100408041C (en) | 2006-04-10 | 2006-04-10 | Medicine composition for treating valval and/or vaginal infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100408041C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014292B1 (en) * | 2008-02-18 | 2010-10-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Medico-prophylactic agent having antibacterial and spermicidal activity |
| CN104490871A (en) * | 2014-11-24 | 2015-04-08 | 江苏远恒药业有限公司 | Compound chlorhexidine acetate suppository, and preparation method thereof |
| CN106074435A (en) * | 2016-06-30 | 2016-11-09 | 浙江安宝药业有限公司 | Rubber of promestriene vagina soft gelatin capsule and preparation method thereof |
| CN111407821A (en) * | 2020-05-06 | 2020-07-14 | 福建深林农业科技有限责任公司 | Pueraria-containing anti-inflammation itching-relieving maintenance and repair washing product |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600315A (en) * | 2003-09-22 | 2005-03-30 | 陈云芳 | Soft capsule combination of Cloquinate/Promestriene in use for vagina |
-
2006
- 2006-04-10 CN CNB2006100720898A patent/CN100408041C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014292B1 (en) * | 2008-02-18 | 2010-10-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Medico-prophylactic agent having antibacterial and spermicidal activity |
| CN104490871A (en) * | 2014-11-24 | 2015-04-08 | 江苏远恒药业有限公司 | Compound chlorhexidine acetate suppository, and preparation method thereof |
| CN106074435A (en) * | 2016-06-30 | 2016-11-09 | 浙江安宝药业有限公司 | Rubber of promestriene vagina soft gelatin capsule and preparation method thereof |
| CN111407821A (en) * | 2020-05-06 | 2020-07-14 | 福建深林农业科技有限责任公司 | Pueraria-containing anti-inflammation itching-relieving maintenance and repair washing product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100408041C (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN100589807C (en) | Compound and its processing technology for compound sulfamonomethoxine sodium injection | |
| CN1278682C (en) | Nanometer preparation of natural vitamin E and its preparation | |
| CN101080250A (en) | Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same | |
| CN1857274A (en) | Medicine composition for treating valval and/or vaginal infection | |
| CN101229126B (en) | Tinidazole compound nano silver microemulsion antibacterial medicine | |
| CN1730097A (en) | Pharmaceutical composition for preventing and curing endometritis and retained afterbirth disease of milk cow | |
| CN1101214C (en) | External use disinfectant anagesic and production thereof | |
| CN1765369A (en) | Nano silver gel and its use | |
| CN101040957A (en) | Medicine for treating skin diseases such as eczema and dermatitis and the method for preparing the same | |
| CN109224024A (en) | For preventing and treating the pharmaceutical composition and its application method of fresh-water fishes bacteria mixed infection | |
| CN102240310A (en) | Blood-sugar-reducing composition and preparation method thereof | |
| CN1850100A (en) | Medicinal composition for treating vagina disease | |
| CN106237029A (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN1857276A (en) | Medicine composition for treating valval and/or vaginal diseases | |
| CN1197571C (en) | Metronidazole, Clotrimazole and Chlorhexidime Acetate preparation and its preparing method | |
| CN1262099A (en) | Albendazole emulsion | |
| CN1299684C (en) | Antibacterial for aquatic animal, preparing method and method of feeding medicine | |
| CN1246005C (en) | Chinese medicine composition for deep fungus infection | |
| CN115531439B (en) | Solid emulsion for promoting sow oestrus and preparation method thereof | |
| CN1113433A (en) | Antiparasitic medicine | |
| CN1272012C (en) | Dermatopathy therapeutic medicine compositions and its preparation method | |
| WO2016155118A1 (en) | Medicine for treating animal eperythrozoonosis and method for preparing same | |
| CN1073096A (en) | The preparation of cantharidia liposoluble pharmaceutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING LANEVA PHARMACEUTICAL CO.,LTD. Assignor: Yang Jun Contract fulfillment period: 2009.9.16 to 2014.9.15 Contract record no.: 2009990001226 Denomination of invention: Medicine composition for treating valval and/or vaginal infection Granted publication date: 20080806 License type: Exclusive license Record date: 20091104 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.16 TO 2014.9.15; CHANGE OF CONTRACT Name of requester: BEIJING LANGYI PHARMACEUTICAL CO., LTD. Effective date: 20091104 |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING LANEVA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YANG JUN Effective date: 20150319 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100020 CHAOYANG, BEIJING TO: 100024 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150319 Address after: 100024 No. 559 Shuangqiao Village, Guan Zhuang Town, Beijing, Chaoyang District Patentee after: BEIJING LANEVA PHARMACEUTICAL CO.,LTD. Address before: 100020, No. 903, building 1302, nine district, Chaoyang District, Beijing, Jinsong Patentee before: Yang Jun |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 101300 No.9 Mintai Road, Beiwu Town, Shunyi District, Beijing Patentee after: Beijing Jincheng Taier Pharmaceutical Co.,Ltd. Address before: 100024 No. 559, shuangqiaoli, Guanzhuang Township, Chaoyang District, Beijing Patentee before: BEIJING LANEVA PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080806 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |